Company News: Healius and Mirvac Bond
Australian Equities sub-portfolio
Healius will benefit from an extension to the existing reimbursement rate for COVID testing. Providers indicate that rates will be extended until March 2021. COVID testing has helped supplement Healius’ income during COVID and delivers high margins. Shares in the company finished the week 8% higher.
The Mirvac Bond (MGRBOND3.UNL) was redeemed earlier this week in full. For most clients, the bond was purchased in May of 2014 and has delivered a return of 37.8% or 5.3% p.a., providing a source of income during a time when commercial property prices were largely driven higher by lower interest rates.